BioCryst Pharmaceuticals Releases New Real-world Data Showing Reduced Attack Rates In Patients With HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO (berotralstat)
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has released new real-world data showing reduced attack rates in patients with Hereditary Angioedema (HAE) with normal C1-inhibitor following long-term treatment with ORLADEYO (berotralstat).
November 10, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals' new data showing the effectiveness of ORLADEYO could potentially boost the company's revenues and reputation in the market.
The new data released by BioCryst Pharmaceuticals shows the effectiveness of their product, ORLADEYO, in reducing attack rates in HAE patients. This could potentially lead to increased sales of the product, thereby boosting the company's revenues. Additionally, the positive data could enhance the company's reputation in the market, potentially attracting more investors and driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100